Developing In Vivo Editing To Target HSCs
Time: 11:30 am
day: Conference Day One
Details:
- Describing how Sana’s Retargetable Fusogen platform directly couples receptor recognition to cell entry, in contrast to endosomal escape delivery systems, enabling high on vs. off-target cell specificity in vitro and in vivo
- Showing development of a T cell-specific fusogen to enable in vivo CAR-T therapy
- Highlighting data showing the progression of HSC in vivo gene editing using a virus-like particle (VLP) system
